NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Healthcare Plans · USD

Progyny, Inc. (PGNY) Stock Analysis

Progyny, Inc. (PGNY) is a Healthcare Plans stock listed on NASDAQ and quoted in US Dollar.

PGNY

$25.94

−$0.67 (−2.52%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PGNY with… →

PGNY Key Statistics

As of Sep 4, 2026
Trading
Open
$26.51
Previous Close
$26.61
Day's Range
25.82–26.67
52-Week Range
16.10–33.07
Volume
1.06M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.99
Valuation
Market Cap
$1.99B
P/E Ratio
29.15
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
11.18
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.52
EPS (ttm)Profit attributable to each share over the last twelve months.
0.89
Financials (FY)
Revenue (FY)
$1.29B+10.40%
Net Income (FY)
$58.52M+7.70%
Profit marginThe share of revenue left as profit after all costs and taxes.
6.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
76.73M
1-Year Return
+10.10%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.21M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PGNY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.01%
2025+48.87%
2024−53.60%
2023+19.36%
2022−38.13%
2021+18.78%
2020+54.43%
2019 (partial year)+72.21%

As of September 4, 2026.

PGNY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.29B$58.52M4.5%
2024$1.17B$54.34M4.7%
2023$1.09B$62.04M5.7%
2022$786.91M$30.36M3.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.29B$304.48M$85.28M$58.52M4.5%
2024$1.17B$253.36M$67.46M$54.34M4.7%
2023$1.09B$238.80M$62.18M$62.04M5.7%
2022$786.91M$167.33M$23.34M$30.36M3.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PGNY Valuation vs Healthcare Plans Median

Median of 11 stocks
MetricPGNYHealthcare Plans medianvs median
P/E29.1525.6614% above
P/S ratio1.520.443.5x the median
Profit margin6.00%1.18%4.8 pts above

Medians across 11 Healthcare Plans stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Progyny, Inc. (PGNY) at $1.99B. The company sits in the Healthcare sector, in the Healthcare Plans industry. The company reports 835 employees.

The most recent close on file for PGNY is $25.94, dated September 4, 2026. That is −$0.67 (−2.52%) against the previous close. The 52-week range on file runs from $16.10 to $33.07. The latest close sits 61.12% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.29B. Against the prior fiscal year total of $1.17B, that is a change of +10.40%. The same year closed with net income of $58.52M. That is +7.70% against the prior fiscal year. Profit margin runs at 6%. That is 4.8 percentage points above the Healthcare Plans median of 1.18%. Earnings per share on a trailing basis come to 0.89.

Across the 4 fiscal years on file, revenue moves from $786.91M in 2022 to $1.29B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

PGNY trades at a trailing price-to-earnings ratio of 29.15. That is 13.6% above the Healthcare Plans median of 25.66. The forward P/E on file is 11.18. Measured against sales, the shares trade at 1.52 times revenue. On price-to-sales that is 3.5 times the Healthcare Plans median of 0.44. 11 Healthcare Plans companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.99. Daily returns over the trailing 6 years annualize to a volatility of 55%. The trailing one-year price return is +10.10%. Across 5 years the annualized return works out at −14.79%.

Growth & Income

No dividend is on file for PGNY.

2026 is still running; the price is +1.01% year to date. Across the complete calendar years on file, 2020 returned +54.43% and 2024 returned −53.60%. Of the 6 complete calendar years on file, 4 finished higher.

Peer Comparison

Progyny, Inc. (PGNY) operates in the Healthcare Plans industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Progyny, Inc. PGNY $1.99B 29.1
UnitedHealth Group Incorporated UNH $356.47B 25.5
CVS Health Corporation CVS $123.73B 25.7
Elevance Health, Inc. ELV $88.37B 18.4

The Healthcare Plans industry average P/E ratio is 25.7x. Progyny, Inc. trades at a P/E of 29.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Healthcare Plans Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 CVS

CVS Health Corporation

$123.73B

 ELV

Elevance Health, Inc.

$88.37B

 CI

The Cigna Group

$74.65B

 HUM

Humana Inc.

$48.22B

 CNC

Centene Corporation

$33.12B
View all Healthcare Plans stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B
View all Healthcare stocks →

About Progyny, Inc.

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Visit website →